Zepbound vs Ozempic: Different Drugs, Different Approvals, Trials and Cost (2026)

Short answer: Zepbound and Ozempic differ in two ways: the molecule and what each is approved for. Zepbound is tirzepatide from Eli Lilly, which acts on GIP and GLP-1 receptors and is approved for chronic weight management and obstructive sleep apnea; Ozempic is semaglutide from Novo Nordisk, which acts on GLP-1 alone and is approved for type 2 diabetes.^[1][2] The closest head-to-head, SURMOUNT-5, compared tirzepatide with semaglutide at Wegovy doses: body weight fell by an average of 20.2% and 13.7% over 72 weeks.^[3]

Whichever one a prescriber chooses, eating well on a smaller appetite matters on both, the subject of our guide to what to eat when you're eating less. General information, not medical advice. Everything below is from the FDA labels, the published trials and the makers' own price pages, as of November 13, 2026.

Zepbound vs Ozempic at a glance

	Zepbound	Ozempic
Maker and molecule	Eli Lilly; tirzepatide (the same molecule as Mounjaro)[1][4]	Novo Nordisk; semaglutide (the same molecule as Wegovy)[2][5]
Receptors	GIP and GLP-1[1]	GLP-1[2]
FDA-approved uses (date)	Chronic weight management in adults with obesity, or overweight plus a weight-related condition (November 8, 2023); moderate to severe obstructive sleep apnea in adults with obesity (December 20, 2024)[6][1]	Blood sugar control in adults with type 2 diabetes (December 5, 2017); lowering cardiovascular risk in type 2 diabetes with heart disease (January 16, 2020); lowering kidney and cardiovascular risk in type 2 diabetes with chronic kidney disease (January 28, 2025)[7][2]
Approved for weight management?	Yes[1]	No; semaglutide's weight-management brand is Wegovy[2][5]
Forms	Weekly injection: single-dose pen, single-dose vials or a 4-dose KwikPen[1]	Weekly injection (pen); separate daily Ozempic tablets for type 2 diabetes[2][8]
Label dose range	Starts at 2.5 mg; maintenance 5, 10 or 15 mg; maximum 15 mg[1]	Starts at 0.25 mg; maintenance 0.5, 1 or 2 mg; maximum 2 mg[2]
Body weight in its own placebo trials	SURMOUNT-1, 72 weeks, no diabetes: −15.0% to −20.9% vs −3.1%. SURMOUNT-2, type 2 diabetes: −12.8% and −14.7% vs −3.2%[1]	30-week diabetes trial: −3.8 kg on 0.5 mg and −4.7 kg on 1 mg vs −1.2 kg (weight was not a main goal)[2]
Closest head to head	SURMOUNT-5, 72 weeks, obesity without diabetes: tirzepatide −20.2% vs semaglutide 1.7 or 2.4 mg (Wegovy doses) −13.7%.[3] SURPASS-2, 40 weeks, type 2 diabetes: tirzepatide −7.6 to −11.2 kg vs semaglutide 1 mg (an Ozempic dose) −5.7 kg[9][4]
Most common digestive adverse reactions (label, drug vs placebo)	5 / 10 / 15 mg: nausea 25% / 29% / 28% vs 8%; diarrhea 19% / 21% / 23% vs 8%; constipation 17% / 14% / 11% vs 5%; vomiting 8% / 11% / 13% vs 2%[1]	0.5 / 1 mg: nausea 15.8% / 20.3% vs 6.1%; diarrhea 8.5% / 8.8% vs 1.9%; vomiting 5% / 9.2% vs 2.3%; constipation 5% / 3.1% vs 1.5%[2]
Boxed warning	The same on both: risk of thyroid C-cell tumors, seen in rodents, human relevance unknown. Not for anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2.[1][2]
Maker's self-pay price (November 2026)	Vials or KwikPen through LillyDirect: $299 a month for 2.5 mg, $399 for 5 mg, $449 for 7.5 to 15 mg with on-time refills[10]	Pen $349 a month for 0.25 to 1 mg, $499 for 2 mg[11]

The weight and adverse reaction rows come from different trials in different people (Zepbound's mostly without diabetes, Ozempic's all with it), so they are not a ranking. Rates from one drug's trials cannot be compared directly with another's.^[1] Each medicine has its own reference page: tirzepatide (Zepbound, Mounjaro) and semaglutide (Ozempic, Wegovy).

Is Ozempic approved for weight management?

No. The Ozempic label lists three uses, all in adults with type 2 diabetes: blood sugar control, lowering cardiovascular risk with heart disease, and lowering kidney and cardiovascular risk with chronic kidney disease.^[2] Semaglutide is approved for chronic weight management as Wegovy, at maintenance doses of 1.7 or 2.4 mg and up to 7.2 mg, above Ozempic's 2 mg maximum.^[5][2]

Prescribing an approved drug for a use not on its label is called off-label use. The FDA says prescribers generally may do it when they judge it right for a patient, but the FDA has not found the drug safe and effective for that use.^[12] So the like-for-like question for body weight is Zepbound against Wegovy, which we cover in full in Zepbound vs Wegovy. And the like-for-like question for type 2 diabetes is Mounjaro against Ozempic: Mounjaro vs Ozempic.

What did the trials comparing tirzepatide and semaglutide find?

No trial has tested Zepbound against Ozempic as products. Two trials compared their molecules:

• SURMOUNT-5 (weight management): 751 adults with obesity and no diabetes, open-label, 72 weeks, each at their maximum tolerated dose, tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg. Body weight changed by −20.2% vs −13.7%, waist by −18.4 vs −13.0 cm.^[3] Those semaglutide doses are Wegovy's, not Ozempic's. Funded by Eli Lilly.
• SURPASS-2 (type 2 diabetes): 1,879 adults on metformin, open-label, 40 weeks, tirzepatide 5, 10 or 15 mg vs semaglutide 1 mg. HbA1c fell 2.01 to 2.30 points vs 1.86, and body weight 1.9 to 5.5 kg more on tirzepatide. Funded by Eli Lilly.^[9]

In both, tirzepatide came out ahead on its main measure. The detailed results tables are on our Zepbound vs Wegovy and Mounjaro vs Ozempic pages, so we do not repeat them here.

Is Zepbound better than Ozempic?

They are built for different jobs, so the question usually becomes "which approved use fits?"

• Body weight, with or without diabetes: Zepbound is approved for it; Ozempic is not. In SURMOUNT-2, in adults with type 2 diabetes, body weight fell by 12.8% and 14.7% on Zepbound 10 and 15 mg vs 3.2% on placebo.^[1]
• Type 2 diabetes with heart or kidney disease: Ozempic carries approvals for cardiovascular risk (SUSTAIN 6: 6.6% vs 8.9% had a heart attack, stroke or cardiovascular death) and kidney risk (FLOW: 18.7% vs 23.2% had a major kidney event or cardiovascular death).^[2] Zepbound has neither; tirzepatide's cardiovascular approval is on the Mounjaro label.^[4]
• Obstructive sleep apnea with obesity: only Zepbound is approved.^[1]
• Form, tolerability and cost, which vary by person and by plan.

How do they work differently?

Semaglutide is a long-acting copy of GLP-1, a gut hormone released after eating: it raises insulin release when blood sugar is high, lowers glucagon, slows stomach emptying and acts on appetite centers in the brain.^[5] Tirzepatide is one molecule that activates the GLP-1 receptor and the receptor for a second gut hormone, GIP; nonclinical studies suggest GIP may add to the regulation of food intake.^[1] Tirzepatide's half-life is about 5 days, semaglutide's about 1 week.^[1][5]

Zepbound and Ozempic dosing: what the labels say

What the FDA labels say — not dosing advice; your prescriber sets your dose.^[1][2]

	Zepbound (weekly injection)	Ozempic (weekly injection)
Starting dose	2.5 mg for 4 weeks	0.25 mg for 4 weeks
Steps	Up by 2.5 mg after at least 4 weeks on each dose	0.5 mg after 4 weeks; then 1 mg, then 2 mg, each after at least 4 weeks, if more blood sugar control is needed
Maintenance	5, 10 or 15 mg (10 or 15 mg for sleep apnea)	0.5, 1 or 2 mg
Missed dose	Take within 4 days; after that, skip it	Take within 5 days; after that, skip it

Zepbound vs Ozempic side effects

Digestive reactions are the most common on both, mostly while the dose is being raised.^[1][2] The label rates in the table above are higher for Zepbound, but they come from different people at different doses: Zepbound's from adults with obesity on up to 15 mg, Ozempic's from adults with type 2 diabetes on up to 1 mg. When tirzepatide and semaglutide were counted in the same trial, SURMOUNT-5, nausea was 43.6% vs 44.4%, vomiting 15.0% vs 21.3% and injection site reactions 8.6% vs 0.3%,^[13] and in SURPASS-2 nausea was 17% to 22% vs 18%.^[9]

Both labels share the same core warnings: pancreatitis, gallbladder disease, kidney injury from dehydration, serious allergic reactions, low blood sugar with insulin or a sulfonylurea, worsening diabetic eye disease, and breathing in stomach contents under anesthesia.^[1][2] Only the Zepbound label advises people on birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase.^[1]

How much do Zepbound and Ozempic cost?

Prices change often. These are the makers' own figures as of November 13, 2026.

• Zepbound, self-pay: vials and multi-dose KwikPens are sold only through LillyDirect, with a prescription.^[14] $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 to 15 mg with on-time refills; otherwise $499 for 7.5 mg and $699 for 10 to 15 mg.^[10]
• Zepbound, with insurance: the single-dose pen can be as little as $25 with commercial coverage, or as low as $499 a month with commercial insurance that does not cover it, under a savings card ending December 31, 2026.^[10]
• Ozempic: the self-pay pen is $349 a month for 0.25 to 1 mg and $499 for 2 mg, with new patients paying $199 for two fills; as little as $25 with commercial coverage.^[11] Novo Nordisk will cut Ozempic's list price to $675 a month from January 1, 2027.^[15]

Medicare. Part D is barred by law from covering drugs used for obesity alone.^[16] The Medicare GLP-1 Bridge, a CMS demonstration from July 1, 2026 to December 31, 2027, gives eligible Part D beneficiaries certain GLP-1 drugs for a $50 copay, with prior authorization,^[17] and Lilly lists Zepbound under it.^[10] Compounded copies of either are not FDA-approved products.^[18]

Switching from Ozempic to Zepbound

Neither label has instructions for switching from the other or a dose conversion. The Zepbound label says not to use it with any GLP-1 receptor agonist, so a switch means stopping one before starting the other, and its schedule starts at 2.5 mg with no exception for people coming from another GLP-1 medication.^[1] Semaglutide stays in the circulation for 5 to 7 weeks after the last dose.^[5] The timing and the dose are your prescriber's decision.

What to eat on either one

Both labels pair the drug with diet and exercise but name no diet.^[1][2] The 2025 joint advisory from four US medical and nutrition societies sets the same priorities for every GLP-1 medication: protein first, small nutrient-dense meals, fiber from food, deliberate fluids and strength training.^[19] Our pages go one question at a time:

• What to eat on Zepbound and what to eat on Wegovy or Ozempic: a small-appetite day, with amounts.
• How much protein on a GLP-1, and the protein calculator.
• Every GLP-1 medication on one map: GLP-1 medications explained.

For transparency about why this page exists on our site: we make one product, Zornava Replenish, a lemon-lime daily hydration and nutrient powder for lighter appetite days, including for people on GLP-1 medications. It is a dietary supplement, not a medication, and it does not replace or imitate any medicine on this page. It is not on sale yet; early access opens February 9, 2027, and the early-access list is open now.